XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.25.1

Investments (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Schedule of Investments [Abstract] |
Schedule of Investments in and Advances to Affiliates | The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three months ended March 31, 2025 and 2024.
(in thousands) |  | For the Three Months Ended March 31, 2025 |  |
Portfolio Company(1) |  | Type |  | Fair Value as of March 31, 2025 |  | Interest & Dividend Income |  | Fee Income |  | Net Change in Unrealized Appreciation (Depreciation) |  | Realized Gain (Loss) |  |  |  |  |  |  |  |
Control Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Coronado Aesthetics, LLC |  | Control |  | $ | 47 |  |  | $ | — |  |  | $ | — |  |  | $ | (22) |  |  | $ | — |  |  |  |  |  |  |  |  |
Gibraltar Acquisition LLC(2) |  | Control |  | 58,900 |  |  | 1,567 |  |  | 39 |  |  | (941) |  |  | — |  |  |  |  |  |  |  |  |
Hercules Adviser LLC(3) |  | Control |  | 45,017 |  |  | 1,900 |  |  | — |  |  | 2,827 |  |  | — |  |  |  |  |  |  |  |  |
Tectura Corporation |  | Control |  | 11,770 |  |  | 170 |  |  | — |  |  | 113 |  |  | — |  |  |  |  |  |  |  |  |
Total Control Investments |  | $ | 115,734 |  |  | $ | 3,637 |  |  | $ | 39 |  |  | $ | 1,977 |  |  | $ | — |  |  |  |  |  |  |  |  |
(in thousands) |  | For the Three Months Ended March 31, 2024 |  |
Portfolio Company(1) |  | Type |  | Fair Value as of March 31, 2024 |  | Interest & Dividend Income |  | Fee Income |  | Net Change in Unrealized Appreciation (Depreciation) |  | Realized Gain (Loss) |  |  |  |  |  |  |  |
Control Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Coronado Aesthetics, LLC |  | Control |  | $ | 283 |  |  | $ | — |  |  | $ | — |  |  | $ | 21 |  |  | $ | — |  |  |  |  |  |  |  |  |
Gibraltar Acquisition, LLC(2) |  | Control |  | 57,931 |  |  | 1,033 |  |  | 36 |  |  | (4,621) |  |  | — |  |  |  |  |  |  |  |  |
Hercules Adviser LLC(3) |  | Control |  | 41,884 |  |  | 1,752 |  |  | — |  |  | 1,171 |  |  | — |  |  |  |  |  |  |  |  |
Tectura Corporation |  | Control |  | 12,117 |  |  | 172 |  |  | — |  |  | 600 |  |  | — |  |  |  |  |  |  |  |  |
Total Control Investments |  | $ | 112,215 |  |  | $ | 2,957 |  |  | $ | 36 |  |  | $ | (2,829) |  |  | $ | — |  |  |  |  |  |  |  |  |
(1)In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of March 31, 2025 and March 31, 2024, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. (2)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (3)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.
Schedule of Investments Portfolio | The following table shows the fair value of the Company’s portfolio of investments by asset class as of March 31, 2025 and December 31, 2024:
(in thousands) | March 31, 2025 |  | December 31, 2024
| Investments at Fair Value |  | Percentage of Total Portfolio |  | Investments at Fair Value |  | Percentage of Total Portfolio
Senior Secured Debt | $ | 3,674,498 |  |  | 93.6 | % |  | $ | 3,419,044 |  |  | 93.4 | %
Unsecured Debt | 64,736 |  |  | 1.7 | % |  | 75,557 |  |  | 2.1 | %
Preferred Stock | 52,662 |  |  | 1.3 | % |  | 53,802 |  |  | 1.5 | %
Common Stock | 94,088 |  |  | 2.4 | % |  | 74,855 |  |  | 2.0 | %
Warrants | 31,473 |  |  | 0.8 | % |  | 30,500 |  |  | 0.8 | %
Investment Funds & Vehicles | 6,993 |  |  | 0.2 | % |  | 6,220 |  |  | 0.2 | %
Total | $ | 3,924,450 |  |  | 100.0 | % |  | $ | 3,659,978 |  |  | 100.0 | %
A summary of the Company’s investment portfolio, at value, by geographic location as of March 31, 2025 and December 31, 2024 is shown as follows:
(in thousands) | March 31, 2025 |  | December 31, 2024
| Investments at Fair Value |  | Percentage of Total Portfolio |  | Investments at Fair Value |  | Percentage of Total Portfolio
United States | $ | 3,489,550 |  |  | 88.9 | % |  | $ | 3,288,737 |  |  | 89.9 | %
Netherlands | 132,889 |  |  | 3.4 | % |  | 59,157 |  |  | 1.6 | %
United Kingdom | 119,905 |  |  | 3.1 | % |  | 142,183 |  |  | 3.9 | %
Switzerland | 56,421 |  |  | 1.5 | % |  | — |  |  | 0.0 | %
Germany | 49,417 |  |  | 1.3 | % |  | 49,255 |  |  | 1.3 | %
Israel | 44,321 |  |  | 1.1 | % |  | 88,066 |  |  | 2.4 | %
Canada | 16,229 |  |  | 0.4 | % |  | 16,251 |  |  | 0.4 | %
Denmark | 9,111 |  |  | 0.2 | % |  | 9,284 |  |  | 0.3 | %
Ireland | 4,647 |  |  | 0.1 | % |  | 4,649 |  |  | 0.1 | %
Singapore | 1,590 |  |  | 0.0 | % |  | 1,996 |  |  | 0.1 | %
Other | 370 |  |  | 0.0 | % |  | 400 |  |  | 0.0 | %
Total | $ | 3,924,450 |  |  | 100.0 | % |  | $ | 3,659,978 |  |  | 100.0 | %
The following table shows the fair value of the Company’s portfolio by industry sector as of March 31, 2025 and December 31, 2024:
(in thousands) | March 31, 2025 |  | December 31, 2024
| Investments at Fair Value |  | Percentage of Total Portfolio |  | Investments at Fair Value |  | Percentage of Total Portfolio
Software | $ | 1,262,813 |  |  | 32.2 | % |  | $ | 1,081,100 |  |  | 29.5 | %
Drug Discovery & Development | 1,119,941 |  |  | 28.5 | % |  | 1,080,390 |  |  | 29.5 | %
Healthcare Services, Other | 625,556 |  |  | 15.9 | % |  | 610,184 |  |  | 16.7 | %
Consumer & Business Services | 374,561 |  |  | 9.6 | % |  | 372,641 |  |  | 10.2 | %
Electronics & Computer Hardware | 167,370 |  |  | 4.3 | % |  | 162,888 |  |  | 4.5 | %
Diversified Financial Services | 117,366 |  |  | 3.0 | % |  | 113,491 |  |  | 3.1 | %
Medical Devices & Equipment | 75,238 |  |  | 1.9 | % |  | 74,962 |  |  | 2.0 | %
Space Technologies | 49,527 |  |  | 1.3 | % |  | 45,700 |  |  | 1.2 | %
Biotechnology Tools | 34,819 |  |  | 0.9 | % |  | 35,434 |  |  | 1.0 | %
Communications & Networking | 27,601 |  |  | 0.7 | % |  | 27,700 |  |  | 0.8 | %
Information Services | 24,923 |  |  | 0.6 | % |  | 24,356 |  |  | 0.7 | %
Sustainable and Renewable Technology | 22,396 |  |  | 0.6 | % |  | 27,696 |  |  | 0.8 | %
Manufacturing Technology | 20,653 |  |  | 0.5 | % |  | 1,162 |  |  | 0.0 | %
Consumer & Business Products | 1,139 |  |  | 0.0 | % |  | 1,497 |  |  | 0.0 | %
Semiconductors | 425 |  |  | 0.0 | % |  | 704 |  |  | 0.0 | %
Media/Content/Info | 114 |  |  | 0.0 | % |  | 63 |  |  | 0.0 | %
Drug Delivery | 8 |  |  | 0.0 | % |  | 10 |  |  | 0.0 | %
Total | $ | 3,924,450 |  |  | 100.0 | % |  | $ | 3,659,978 |  |  | 100.0 | %
The following table summarizes information related to our SBICs as of March 31, 2025 and December 31, 2024.
|  | March 31, 2025 |  | December 31, 2024
Description |  | HC IV | SBIC V |  | HC IV | SBIC V
Number of investments held |  | 35 | 14 |  | 33 | 11 |
Fair value of investments (in millions) |  | $ | 376.1 | $ | 194.7 |  | $ | 377.7 | $ | 155.6 |
Percentage of fair value of investments based on the Company's total investment portfolio |  | 9.6 | % | 5.0 | % |  | 10.3 | % | 4.3 | %
Tangible assets (in millions) |  | $ | 381.4 | $ | 197.6 |  | $ | 382.9 | $ | 157.8 |
Percentage of tangible assets based on the Company's total assets |  | 9.5 | % | 4.9 | % |  | 10.0 | % | 4.1 | %
Schedule of Investment Collateral | The Company's investments were collateralized as follows as of March 31, 2025 and December 31, 2024:
| Percentage of debt investments (at fair value), as of
| March 31, 2025 |  | December 31, 2024
Senior Secured First Lien |  |  |
All assets including intellectual property | 69.0 | % |  | 67.1 | %
All assets with negative pledge on intellectual property | 13.8 | % |  | 14.2 | %
“Last-out” with security interest in all of the assets | 8.1 | % |  | 9.7 | %
Total senior secured first lien position | 90.9 | % |  | 91.0 | %
Second lien | 7.4 | % |  | 6.8 | %
Unsecured | 1.7 | % |  | 2.2 | %
Total debt investments at fair value | 100.0 | % |  | 100.0 | %
Summary of Fair Value and Location of the Company's Derivative Instruments | The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of March 31, 2025 and December 31, 2024:
(in thousands) |  | Fair Value
Derivative Instrument | Statement Location |  | March 31, 2025 |  | December 31, 2024
Foreign currency forward contract | Other assets |  | $ | — |  |  | $ | 538 |
Foreign currency forward contract | Accounts payable and accrued liabilities |  | 301 |  |  | — |
| Total |  | $ | 301 |  |  | $ | 538 |
Summary of Net Realized and Unrealized Gains and Losses | Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three months ended March 31, 2025 and 2024 are in the following locations in the Consolidated Statements of Operations:
(in thousands) |  |  | Three Months Ended March 31, |  |
Derivative Instrument | Statement Location |  | 2025 |  | 2024 |  |  |  |
Foreign currency forward contract | Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments |  | $ | (840) |  |  | $ | 229 |  |  |  |  |
| Total |  | $ | (840) |  |  | $ | 229 |  |  |  |  |
Schedule of Investment Interest Income and Fee Income | The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows:
(in thousands) | Three Months Ended March 31, |  |
| 2025 |  | 2024 |  |  |  |
Contractual interest income | $ | 87,817 |  |  | $ | 90,714 |  |  |  |  |
Exit fee interest income | 10,228 |  |  | 11,880 |  |  |  |  |
PIK interest income | 13,473 |  |  | 9,897 |  |  |  |  |
Dividend income | 2,400 |  |  | 1,600 |  |  |  |  |
Other investment income(1) | 1,654 |  |  | 1,688 |  |  |  |  |
Total interest and dividend income | $ | 115,572 |  |  | $ | 115,779 |  |  |  |  |
Recurring fee income | $ | 2,680 |  |  | $ | 2,455 |  |  |  |  |
Fee income - expired commitments | 317 |  |  | 647 |  |  |  |  |
Accelerated fee income - early repayments | 942 |  |  | 2,672 |  |  |  |  |
Total fee income | $ | 3,939 |  |  | $ | 5,774 |  |  |  |  |
(1)Other investment income includes OID interest income and interest recorded on other assets.
Schedule of Unamortized Capitalized Fee Income | As of March 31, 2025 and December 31, 2024, unamortized capitalized fee income was recorded as follows:
(in millions) | March 31, 2025 |  | December 31, 2024
Offset against debt investment cost | $ | 37.2 |  |  | $ | 36.9 |
Deferred obligation contingent on funding or other milestone | 10.2 |  |  | 9.1 |
Total Unamortized Fee Income | $ | 47.4 |  |  | $ | 46.0 |
Schedule of Loan Exit Fees Receivable | As of March 31, 2025 and December 31, 2024, loan exit fees receivable were recorded as follows:
(in millions) | March 31, 2025 |  | December 31, 2024
Included within debt investment cost | $ | 41.5 |  |  | $ | 39.2 |
Deferred receivable related to expired commitments | 2.9 |  |  | 3.0 |
Total Exit Fees Receivable | $ | 44.4 |  |  | $ | 42.2 |

X
- Definition Schedule of Loan Exit Fees Receivable [Table Text Block] + References No definition available. + Details
Name: | htgc_ScheduleOfLoanExitFeesReceivableTableTextBlock
Namespace Prefix: | htgc_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule Of Unamortized Capitalized Fee Income + References No definition available. + Details
Name: | htgc_ScheduleOfUnamortizedCapitalizedFeeIncomeTableTextBlock
Namespace Prefix: | htgc_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-22 + Details
Name: | us-gaap_FairValueConcentrationOfRiskTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 + Details
Name: | us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details
Name: | us-gaap_InvestmentIncomeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investments in and advances to affiliates. Does not include the tabular disclosure of the disaggregation of investments in and advances to affiliates across legal entities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details
Name: | us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details
Name: | us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details
Name: | us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ScheduleOfInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration